Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved April 1996

Specific Treatments:

colorectal cancer

General Information

CEA is expressed by more than 90% of colorectal cancers, as well as by a large number of other carcinomas, including esophageal, stomach, lung, breast, pancreas, uterus, and ovarian cancer. It has been shown that this tumor marker can serve as a useful target for radiolabeled antibodies. Since CEA-Scan uses a small antibody fragment at a low dose, there is virtually no immune reaction by subjects to the foreign protein. In addition, linking the fragment with technetium-99m, a common radioisotope in nuclear medicine, permits tumor detection within a few hours, using conventional gamma cameras.

Mechanism of Action

CEA-Scan comprises an antibody fragment (Fab') against the tumor marker, carcinoembryonic antigen ("CEA").

Additional Information

Each year there are approximately 134,000 new cases of colorectal cancer in the United States; colorectal cancer is estimated to kill over 55,000 Americans annually. Trials are also under way for lung and breast cancer indications.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation